Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CureVac N.V. stock logo
CVAC
CureVac
$5.40
-0.1%
$4.46
$2.37
$5.72
$1.22B2.53783,243 shs751,012 shs
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
$12.96
-0.4%
$14.62
$10.60
$38.12
$1.37B0.251.19 million shs361,183 shs
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$15.00
+1.1%
$16.72
$7.93
$25.29
$1.33B0.721.62 million shs663,493 shs
YS Biopharma Co., Ltd. stock logo
YSB
YS Biopharma
$1.25
$0.35
$1.78
$344.32M0.51172,401 shs63,510 shs
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CureVac N.V. stock logo
CVAC
CureVac
0.00%+0.28%+20.96%+108.30%+72.92%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
0.00%-1.63%-12.58%+12.55%-29.13%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
0.00%+1.56%+1.90%+0.07%+88.92%
YS Biopharma Co., Ltd. stock logo
YSB
YS Biopharma
0.00%0.00%0.00%0.00%+563.61%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CureVac N.V. stock logo
CVAC
CureVac
4.6422 of 5 stars
4.15.00.04.91.00.01.3
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
2.6464 of 5 stars
3.43.00.00.02.62.50.0
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
3.1711 of 5 stars
4.43.00.00.01.70.80.6
YS Biopharma Co., Ltd. stock logo
YSB
YS Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CureVac N.V. stock logo
CVAC
CureVac
2.20
Hold$6.8326.66% Upside
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
2.80
Moderate Buy$40.00208.76% Upside
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
2.87
Moderate Buy$32.14114.29% Upside
YS Biopharma Co., Ltd. stock logo
YSB
YS Biopharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest YSB, EWTX, TVTX, and CVAC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$30.00
6/30/2025
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$42.00
6/26/2025
CureVac N.V. stock logo
CVAC
CureVac
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Neutral$12.00 ➝ $5.50
6/13/2025
CureVac N.V. stock logo
CVAC
CureVac
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$7.00 ➝ $5.00
6/12/2025
CureVac N.V. stock logo
CVAC
CureVac
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeMarket Perform
6/12/2025
CureVac N.V. stock logo
CVAC
CureVac
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/11/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$30.00
6/11/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$35.00 ➝ $32.00
6/5/2025
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$48.00
5/28/2025
CureVac N.V. stock logo
CVAC
CureVac
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$10.00
5/16/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CureVac N.V. stock logo
CVAC
CureVac
$579.18M2.09$0.86 per share6.24$3.36 per share1.61
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/AN/AN/AN/A$4.84 per shareN/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$233.18M5.71N/AN/A$0.76 per share19.74
YS Biopharma Co., Ltd. stock logo
YSB
YS Biopharma
$560.76M0.00N/AN/A$1.14 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CureVac N.V. stock logo
CVAC
CureVac
$175.50M$0.925.86N/AN/A35.44%30.89%25.54%8/13/2025 (Estimated)
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$133.81M-$1.55N/AN/AN/AN/A-30.95%-29.45%8/6/2025 (Estimated)
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$321.55M-$2.81N/AN/AN/A-82.88%-1,179.73%-41.10%7/30/2025 (Estimated)
YS Biopharma Co., Ltd. stock logo
YSB
YS Biopharma
-$21.17MN/A0.00N/AN/AN/AN/AN/AN/A

Latest YSB, EWTX, TVTX, and CVAC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/22/2025Q1 2025
CureVac N.V. stock logo
CVAC
CureVac
-$0.16-$0.24-$0.08-$0.24$4.27 million$0.94 million
5/8/2025Q1 2025
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$0.45-$0.43+$0.02-$0.43N/AN/A
5/1/2025Q1 2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$0.55-$0.47+$0.08-$0.47$77.44 million$81.73 million
4/10/2025Q4 2024
CureVac N.V. stock logo
CVAC
CureVac
-$0.14-$0.15-$0.01-$0.15$6.40 million$15.44 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CureVac N.V. stock logo
CVAC
CureVac
N/AN/AN/AN/AN/A
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/AN/AN/AN/AN/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/AN/AN/AN/AN/A
YS Biopharma Co., Ltd. stock logo
YSB
YS Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CureVac N.V. stock logo
CVAC
CureVac
0.05
7.65
7.64
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/A
20.99
20.99
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
9.46
2.05
2.03
YS Biopharma Co., Ltd. stock logo
YSB
YS Biopharma
0.26
0.94
0.73

Institutional Ownership

CompanyInstitutional Ownership
CureVac N.V. stock logo
CVAC
CureVac
17.26%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/A
YS Biopharma Co., Ltd. stock logo
YSB
YS Biopharma
52.64%

Insider Ownership

CompanyInsider Ownership
CureVac N.V. stock logo
CVAC
CureVac
2.15%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
23.20%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
4.19%
YS Biopharma Co., Ltd. stock logo
YSB
YS Biopharma
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
CureVac N.V. stock logo
CVAC
CureVac
880224.34 million219.52 millionOptionable
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
60105.20 million80.79 millionOptionable
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
46088.81 million85.08 millionOptionable
YS Biopharma Co., Ltd. stock logo
YSB
YS Biopharma
77393.06 millionN/ANot Optionable

Recent News About These Companies

YS Life
LakeShore changes CEO with new executive appointments
LakeShore Biopharma Co Ltd Ordinary Shares LSB
LSB LakeShore Biopharma Co., Ltd
YS Stock Earnings: YS Biopharma Co Misses EPS, Beats Revenue for Q3 2024

New MarketBeat Followers Over Time

Media Sentiment Over Time

CureVac stock logo

CureVac NASDAQ:CVAC

$5.40 -0.01 (-0.09%)
As of 07/3/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Edgewise Therapeutics stock logo

Edgewise Therapeutics NASDAQ:EWTX

$12.96 -0.06 (-0.42%)
Closing price 07/3/2025 01:04 PM Eastern
Extended Trading
$12.96 0.00 (0.00%)
As of 07/3/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Travere Therapeutics stock logo

Travere Therapeutics NASDAQ:TVTX

$15.00 +0.16 (+1.08%)
Closing price 07/3/2025 01:04 PM Eastern
Extended Trading
$15.00 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

YS Biopharma stock logo

YS Biopharma NASDAQ:YSB

YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.